Product
CS-101
Aliases
CS-101 injection
5 clinical trials
2 indications
Indication
β-Thalassemia MajorIndication
Beta ThalassemiaClinical trial
A Single-arm, Open-label Phase I Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamic Profile of a Single Dose of CS-101 Injection in Subjects With β-thalassemia MajorStatus: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Clinical Study Evaluating the Safety and Efficacy of In-vitro tBE Edited Autologous Hematopoietic Stem Progenitor Cells(CS-101) in Treating Subjects With β-thalassemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
A Clinical Study Evaluating the Safety and Efficacy of In-vitro tBE Edited Autologous Hematopoietic Stem Progenitor Cells(CS-101) in Treating Subjects With β-thalassemiaStatus: , Estimated PCD: 2025-12-31
Clinical trial
Evaluation and Promotion of Key Technologies of Base-edited Autologous Hematopoietic Stem Cell Transplantation in Treating Patients With β-thalassemia MajorStatus: Recruiting, Estimated PCD: 2024-10-16
Clinical trial
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) TransplantationStatus: Recruiting, Estimated PCD: 2026-12-01